These innovative molecules represent a significant advancement in the therapy of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in lowering blood glucose levels. https://tamzinwdud401991.newsbloger.com/39794345/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide